Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce further positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). The Company was provided with data from the Study that indicates the response in a pre-clinical triple negative breast cancer model treated with the combination of Sona's targeted hyperthermia therapy ("THT") and interleukin-2 ("IL-2"), a standard immunotherapy, is statistically significantly superior to results observed from treatment with either agent individually or the control group. This second phase of the Study has documented that, in a cohort of six animals, 6/6 of treated triple negative breast cancer, the most aggressive and therapy resistant form, mouse tumors bearing gold nanorods and IL-2 responded to the combination therapy, resulting in a flattening of the tumor growth curves, as shown in the below graph. The generation of hyperthermia involved exposing tumors previously injected intratumorally with Sona's gold nanorods and IL-2 to a single dose of near infrared light.

Halifax, Nova Scotia--(Newsfile Corp. - April 8, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces that it has been approved for funding totaling approximately $40,000 to support the development of its intellectual property portfolio.